Abstract: The invention relates to compounds of general formula (I), a method for the production thereof and the use thereof as pharmacologically effective substances for a broad medical indication spectrum. Furthermore, selective adenosine receptor ligands, preferably selective adenosine A1-, adenosine A2a- and/or adenosine A2b-receptor ligands are provided for the prophylaxis and/or the treatment of diseases, especially cardiovascular diseases, diseases of the urogenital region, diseases of the respiratory tract, inflammatory and neuroinflammatory diseases, diabetes, especially pancreatic diabetes, neurodegenerative diseases, pain states, cancer as well as liver fibrosis and liver cirrhosis.

Abstract: The invention relates to compounds of general formula (I), a method for the production thereof and the use thereof as pharmacologically effective substances for a broad medical indication spectrum. Furthermore, selective adenosine receptor ligands, preferably selective adenosine A1-, adenosine A2a- and/or adenosine A2b-receptor ligands are provided for the prophylaxis and/or the treatment of diseases, especially cardiovascular diseases, diseases of the urogenital region, diseases of the respiratory tract, inflammatory and neuroinflammatory diseases, diabetes, especially pancreatic diabetes, neurodegenerative diseases, pain states, cancer as well as liver fibrosis and liver cirrhosis.

Abstract: This application relates to compounds of formula (I), wherein R1, R2, R3, and R4 are defined as recited in the claims, or a tautomer, salt, hydrate, or alkoxide thereof. A process for preparing such materials, pharmaceutical compositions containing them, and methods of treating a cardiovascular disorder by administering them to a patient are also disclosed and claimed.

Abstract: The present invention relates to the use of microbiologically prepared compounds and their mixtures, which are called efomycins, as performance promoters in farm animals and processes for their preparation, and furthermore new efomycins and their mixtures as new chemical compounds. The invention also relates to microorganisms which can be used for the preparation of the efomycins and their mixtures.

Abstract: An animal growth promoter, efomycin G, is obtained by culturing Streptomycetes strain BS 1261. Efomycin G has the following properties:(a) The empirical formula: C.sub.53 H.sub.86 O.sub.18(b) The mass spectrum (fast atom bombardment) Molecular weight+Na.sup.+ : 1033(c) The .sup.1 H-nuclear magnetic resonance spectrum, stated in parts per million, shown in FIG. 1.(d) The .sup.13 C-nuclear magnetic resonance spectrum, stated in parts per million shown in FIG. 2, with chemical shifts of the CC-NMR signals as follows:______________________________________ 170.0 77.9 65.9 32.9 7.0 145.4 73.4 48.5 19.4 144.7 71.2 43.6 19.1 131.9 70.6 41.9 16.8 121.1 70.1 41.1 16.7 99.6 69.9 38.8 15.1 99.5 66.9 38.5 13.4 93.6 66.5 36.2 9.0 93.3 66.4 33.0 8.9 ______________________________________ (ppm values are relative to tetramethylsilane at 0 ppm)(e) A UV absorption maximum at 251-254 nm in methanolic solution(f) The structure according to FIG. 3.

Abstract: Promoting the growth of animals with a novel compound, named annomycin, by cultivation of Streptomyces strain BS 572, DSM 3817.

Abstract: A novel antibiotic for combating bacteria and promoting animal growth is obtained by cultivating Streptomyces strain BA 9.